Relevant bibliographies by topics / Immunoadsorption

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Immunoadsorption'

Author: Grafiati
Published: 4 June 2021
Last updated: 3 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immunoadsorption.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immunoadsorption"

1

Weinmann, Werner, Koenig, Rottbauer, Walcher, and Keßler. "Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy." Biomolecules 9, no. 11 (2019): 654. http://dx.doi.org/10.3390/biom9110654.

Full text
Abstract:
Immunoadsorption and subsequent administration of intravenous immunoglobulin (IVIG) have shown beneficial effects on cardiac function and symptoms in patients with dilated cardiomyopathy. Biomarkers play an emerging role in disease monitoring and outcome prediction of heart failure (HF) patients. We aimed to analyze cardiac biomarkers as predictor for improvement of left ventricular (LV) function after immunoadsorption treatment in dilated cardiomyopathy (DCM). Thirty-one patients with dilated cardiomyopathy on optimized HF pharmacotherapy received a single cycle of immunoadsorption for five days followed by IVIG administration. Left ventricular ejection fraction (LVEF) and heart failure biomarkers (hs troponin T, hs troponin I, NT-proBNP and sST2) were evaluated before treatment, after the last cycle of immunoadsorption and during a median follow-up of 30.5 months. We correlated HF biomarkers before immunoadsorption and acute changes of HF biomarkers by immunoadsorption with LV improvement during the long-term follow-up. LV function improved significantly after immunoadsorption from 28.0 to 42.0% during the long-term follow-up (p < 0.0001). Evaluation of biomarker levels showed a significant decrease for hs troponin I (from 9.2 to 5.5 ng/L, p < 0.05) and NT-proBNP (from 789.6 to 281.2 pg/mL, p < 0.005). Correlation of biomarker levels before immunoadsorption and LVEF at the long-term follow-up show good results for hs troponin T (r = −0.40, r2 = 0.16, p < 0.05), hs troponin I (r = −0.41, r2 = 0.17, p < 0.05) and sST2 (r = −0.46, r2 = 0.19, p < 0.05). Correlation of biomarker levels before immunoadsorption and the individual increase in LV function was significant for hs troponin T (r = −0.52, r2 = 0.27, p < 0.005) and hs troponin I (r = −0.53, r2 = 0.29, p < 0.005). To imply a tool for monitoring outcome immediately after immunoadsorption treatment, we investigated the correlation of acute changes of biomarker levels by immunoadsorption treatment and individual increase in LV function. A drop in hs troponin T (r = −0.41, r2 = 0.17, p < 0.05) and hs troponin I (r = −0.53, r2 = 0.28, p < 0.005) levels demonstrate a good correlation to improvement in LVEF during the long-term follow-up. Conclusion: Hs troponin T and I levels correlate with LV function improvement during long-term follow-up. Acute decrease of troponins by immunoadsorption treatment is paralleled by individual improvement of LVEF at the long-term follow-up. Thus, troponins could serve as a monitoring tool for the improvement of LV function after immunoadsorption treatment in dilated cardiomyopathy.
APA, Harvard, Vancouver, ISO, and other styles
2

Eming, Rüdiger, and Michael Hertl. "Immunoadsorption in pemphigus." Autoimmunity 39, no. 7 (2006): 609–16. http://dx.doi.org/10.1080/08916930600972040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bertram, Juergen H., Frank R. Jones, and Joseph P. Balint. "Protein A Immunoadsorption." Clinical Immunotherapeutics 6, no. 3 (1996): 211–27. http://dx.doi.org/10.1007/bf03259520.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schmidt, Enno, and Detlef Zillikens. "Immunoadsorption in dermatology." Archives of Dermatological Research 302, no. 4 (2010): 241–53. http://dx.doi.org/10.1007/s00403-009-1024-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Meyersburg, Damian, Enno Schmidt, Michael Kasperkiewicz, and Detlef Zillikens. "Immunoadsorption in Dermatology." Therapeutic Apheresis and Dialysis 16, no. 4 (2012): 311–20. http://dx.doi.org/10.1111/j.1744-9987.2012.01075.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Henderson, L. W. "Blood Purification by Immunoadsorption." Blood Purification 18, no. 2 (2000): 148. http://dx.doi.org/10.1159/000014439.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nicuolo, A., N. Braun, and T. Risler. "Technical basis for immunoadsorption." EDTNA-ERCA Journal 26, no. 3 (2000): 20–26. http://dx.doi.org/10.1111/j.1755-6686.2000.tb00099.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dörffel, Wolf V., Gert Wallukat, Gert Baumann, and Stephan B. Felix. "Immunoadsorption in Dilated Cardiomyopathy." Therapeutic Apheresis 4, no. 3 (2000): 235–38. http://dx.doi.org/10.1046/j.1526-0968.2000.00177.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ota, Kohei, Yuko Shimizu, Hisae Ichikawa, et al. "Neutrophil Activation in Immunoadsorption." Therapeutic Apheresis 4, no. 3 (2000): 229–34. http://dx.doi.org/10.1046/j.1526-0968.2000.00191.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wakabayashi, Y., A. Baba, M. Akaishi, T. Yoshikawa, and T. Monkawa. "Immunoadsorption in dilated cardiomyopathy." Critical Care 13, Suppl 1 (2009): P279. http://dx.doi.org/10.1186/cc7443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immunoadsorption"

1

Vallar, Laurent. "Développement et validation in vitro d'une procédure d'immunoépuration destinée à l'élimination spécifique de la bêta-2 microglobuline à partir de sang total chez les patients insuffisants rénaux chroniques dialysés : une approche thérapeutique potentielle pour prévenir et traiter l'amyloïdose associée à la dialyse périodique." Nancy 1, 1996. http://www.theses.fr/1996NAN19002.

Full text
Abstract:
Le traitement palliatif de l'insuffisance rénale par dialyse périodique a très fréquemment pour conséquence à long terme l'apparition d'une nouvelle forme d'amyloïdose caractérisée par la formation de dépôts protéiques constitués en grande partie de bêta-2 microglobuline (bêta 2-M). Ces dépôts ont une affinité élective principalement pour les structures ostéoarticulaires, et sont associés à des manifestations cliniques souvent douloureuses et parfois très invalidantes. La pathogénie de l'affection est encore mal connue mais un rôle important est attribué à la rétention massive et prolongée de la bêta 2-M qui est observée chez tous les dialysés chroniques. Il semble donc qu'une élimination intensive de la bêta 2-M pourrait certainement permettre de ralentir la progression de la maladie, voire même de prévenir son apparition. Dans ce contexte, la technique d'immunoépuratlon par voie extracorporelle constitue une approche thérapeutique tout à fait séduisante. Une procédure d'immunoadsorption de la bêta 2-M a été mise au point au stade du laboratoire. Pour ce faire, six anticorps monoclonaux et des anticorps polyclonaux, tous dirigés contre la bêta 2-M humaine, ont été développés, puis soumis à un examen attentif de leur spécificité et de leurs capacités de fixation et de désorption dans les conditions dynamiques caractéristiques de la chromatographie liquide basse pression. Des immunoadsorbants ont été préparés en immobilisant un des anticorps monoclonaux, sélectionné sur la base de ses excellentes propriétés de ligand d'affinité, sur divers supports chromatographique activés au bromure de cyanogène, Ces matrices, constituées de microparticules d'agarose réticulé (Sepharose® 6 MB) ou de fibres creuses de Cuprophane™ (hémodialyseurs) ou de polystjffone revêtu d'hydroxyéthylcellulose (modules TRIO-purifier®), ont été choisies en raison de leur hémocompatibilité potentielle. Une analyse comparative de leur efficacité d'épuration a montré que les supports d'affinité à base de Sepharose® 6 MB étaient les plus performants du point de vue de la capacité d'adsorption, de la spécificité et de la stabilité. A partir de ces systèmes, une procédure d'immunoadsorption a été développée, et ses modalités optimales d'utilisation ont été définies avec précision. Le dispositif a ensuite été validé lors d'une étude réalisée in vitro en présence de sang total. Il a été montré à cette occasion que 80 à 85 µg de bêta 2-M par milligramme d'anticorps immobilisés pouvaient être extraits de façon spécifique et sans perturbation majeure de la numération et de la formule sanguines. Au regard de ses performances tout à fait encourageantes, la technique pourrait potentiellement être utilisée chez les patients insuffisants rénaux chroniques dialysés pour éliminer la bêta 2-M à partir de sang total directement au cours des séances d'hémodialyse. La faisabilité et l'efficacité à long terme d'un tel traitement devront être démontrées lors d'une phase ultérieure d'expérimentation clinique.
APA, Harvard, Vancouver, ISO, and other styles
2

Subramanian, Anuradha. "Identification of the factors impacting immunosorbent performance." Diss., Virginia Tech, 1993. http://hdl.handle.net/10919/38450.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Collomb, Jocelyne. "Approche moléculaire et physico-chimique de la détection du coronavirus entérique bovin dans l'environnement." Nancy 1, 1991. http://docnum.univ-lorraine.fr/public/SCD_T_1991_0453_COLLOMB.pdf.

Full text
Abstract:
Une étude de la structure moléculaire et des caractéristiques physicochimiques du coronavirus entérique bovin (BECV) a été envisagée afin de développer des techniques de détection de ce virus dans les milieux biologiques et l'environnement. Le clonage de l'ARN génomique a été réalisé dans E. Coli. L'analyse de la banque d'ADNc obtenue a permis de sélectionner un fragment de 2 kb, comprenant la majeure partie des gènes codant pour les protéines virales N et M, et utilisé comme sonde pour la mise au point d'un test d'hybridation moléculaire par slot blot. Deux techniques de marquage de la sonde ont été comparées : marquage radioactif au 32p et marquage enzymatique par couplage covalent à la péroxydase et révélation par chimiluminescence. La sonde radioactive permet de détecter 1 à 3 pg d'ARN viral, soit 2. 105 génomes, tandis que la sonde enzymatique, moins sensible, limite la détection à 100 pg d'ARN. Le test s'est avéré applicable à la détection du BECV produit en culture de cellules HRT 18 et présent dans les fécès de veaux atteints d'entérite. La recherche du BECV dans le milieu hydrique nécessite une étape de concentration préalable faisant intervenir les caractéristiques physicochimiques et antigéniques du virus. Ainsi, une technique d'immunoaffinité utilisant des anticorps monoclonaux et un procédé d'adsorption-élution sur poudre de verre ont été analysés. Dans chacun des cas, l'isolement des virus dispersés dans l'eau est efficace. Leur élution du support, par dissociation de l'immuncomplexe ou par répulsion électrostatique, entraîne une dégradation de l'enveloppe virale empêchant toute mise en évidence par inoculation à des cellules HRT 18. En revanche, les virus concentrés ont pu être détectés par hybridation moléculaire. La conduite d'études épidémiologiques nécessitera cependant d'améliorer le seuil de détection par amplification du système de révélation ou du matériel nucléique viral.
APA, Harvard, Vancouver, ISO, and other styles
4

Huguet, Hélène-Céline. "Développement d'un adsorbant synthétique pour un procédé d'épuration plasmatique destiné au traitement de patients hémophiles A sensibilisés." Paris 11, 2004. http://www.theses.fr/2004PA114809.

Full text
Abstract:
L'apparition d'allo-anticorps anti-facteur VIII (FVIII) est une grave complication des traitements des patients hémophiles A. L'élimination sélective de ces inhibiteurs de FVIII qui neutralisent l'activité fonctionnelle du FVIII exogène, à l'aide d'un procédé d'épuration plasmatique constitué d'un adsorbant purement synthétique est une stratégie thérapeutique pertinente pour traiter les patients hémophiles A atteints. Des adsorbants constitués de billes de polystyrène fonctionnalisé par des groupements sulfonates et sulfamides de l'ester méthylique de la L-tyrosine qui miment des sites de reconnaissance du FVIII par des anticorps, présentent une capacité à retenir sélectivement les inhibiteurs. Les propriétés d'adsorption de ces résines ont été analysées dans des conditions proches de leur utilisation en clinique, en simulant une immunoadsorption thérapeutique. Le but de ces études consistait à développer un nouvel immunoadsorbant pour le traitement de patients hémophiles A sensibilisés<br>The occurrence of anti-factor VIII (FVIII) allo-antibodies is a severe complication of the treatment of haemophilia A patients, leading to the inhibition of transfused FVIII activity. The selective elimination of these inhibitory antibodies using immunoadsorption device employing purely synthetic adsorbers, is of interest in the treatment strategy of haemophilia A patients with inhibitors. Adsorbers consisting of polystyrene-based beads substituted with sulphonate and L-tyrosyl methylester groups, which mimic par of epitope of FVIII recognized by inhibitors, exhibit selective binding capacities towards anti-FVIII antibodies. These adsorbers were investigated as regards to their adsorption capacity by simulating a therapeutic immunoadsorption in order to reproduce condition to be encountered in clinical setting. The final aim of these studies was to define an innovative medical device for the management of haemophilia A patients with inhibitors
APA, Harvard, Vancouver, ISO, and other styles
5

Bhardwaj, Gourav [Verfasser]. "Proteomic analysis of endomyocardial biopsies and plasma of dilated cardiomyopathy patients treated by immunoadsorption therapy / Gourav Bhardwaj." Greifswald : Universitätsbibliothek Greifswald, 2016. http://d-nb.info/1119751233/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Michaely, Jean-Pierre. "Conception et réalisation d'un appareil informatisé pour l'automatisation du processus d'immunoépuration de plasma hypercholesterolemique en circulation extracorporelle." Vandoeuvre-les-Nancy, INPL, 1993. http://www.theses.fr/1993INPL002N.

Full text
Abstract:
La gestion simultanée des phases d'adsorption et de régénération d'un système d'immunoépuration en continu du plasma serait largement facilitée et sécurisée par l'emploi d'une machine automatique microinformatisée. Deux colonnes d'immunoadsorbant fonctionneront en alternance, tantôt en épuration, tantôt en régénération. Cela permet de limiter le volume extracorporel et d'optimiser la durée du traitement. La synchronisation du fonctionnement entre les deux colonnes est assurée par le contrôle de cette phase. Un spectrophotomètre et un pH-mètre permettent de suivre l'évolution du cycle de régénération. Les signaux de ces deux appareils enregistrés en continu, commandent la commutation des vannes. Compte-tenu de l'utilisation in vivo de la machine, un accent particulier a été mis sur la sécurité apportée au fonctionnement. La pression amont des colonnes est contrôlée de façon à détecter toute anomalie des circuits. Le spectrophotomètre et le pH-mètre contrôlent en continu les fluides. Le plasma est recueilli dans une poche tampon depuis la machine primaire de séparation cellules/plasma. Son volume est mesure en continu. En cas d'accroissement anormal, un retour direct du plasma au patient est assure par un by-pass. Les positions relatives des vannes sont contrôlées. Le dialogue operateur/système est assuré par la combinaison d'un clavier dédié et d'un écran vidéo couleur
APA, Harvard, Vancouver, ISO, and other styles
7

Grovender, Eric A. "A fluidized immunoadsorption device for removing beta-2-microglobulin from whole blood : a potential treatment for dialysis-related amyloidosis." Thesis, Massachusetts Institute of Technology, 2003. http://hdl.handle.net/1721.1/16931.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2003.<br>Page 126 blank.<br>Includes bibliographical references (p. 113-114).<br>This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.<br>Dialysis-related amyloidosis (DRA) is a frequent complication of end-stage renal disease that has been associated with the accumulation of 2-microglobulin (2m). Excluding transplantation, existing kidney replacement technologies are believed to remove insufficient quantities of P2m for the prevention of DRA, as they are non-specific and based on size-exclusion. A proposed DRA therapy is to use immunoadsorptive particles within an extracorporeal Vortex Flow Plasmapheretic Reactor (VFPR) to specifically remove 2m from blood. The compartmental design of the VFPR allows for the use of small adsorbent particles (100 m) that possess inherent mass-transfer advantages over the larger ones (>400 gIm) that are required for safe contact with whole blood for this application. Demonstrating the efficacy of this technology as a therapy for DRA would support its tailored application for treating other pathologies that are caused by circulating compounds such as sepsis, liver failure, autoimmune disease, drug overdoses, and genetic disorders. Whole anti-P2m antibodies (BBM.1) were immobilized onto agarose beads and used within a VFPR to remove donor baseline and defined quantities of recombinant 32m from whole human blood, in vitro. A dynamic immunoadsorption model was developed for the VFPR that was based upon the independent characterization of the mass-transfer processes within the VFPR and the thermodynamics of the immunoadsorbent. The experimentally-observed and model-predicted dynamics of 32m clearance from the blood indicate that the process controlling the rate of P2m removal was the hemofiltration rate (50 mL-plasma/min), which was on the order of the reported supply rate of 2m into the vasculature (70 mL-plasma/min).<br>(cont.) Single-chain variable region (scFv) antibody fragments offer several potential advantages over whole antibodies due to their size and genetic definition, as well as their amenability for microbial expression and in vitro evolution. Hence, a BBM.1 scFv was expressed by a yeast display vector and its affinity was quantified with a fluorescence-activated cell sorter (KD = 0.008 +/-proposed therapy to treat and/or prevent DRA.<br>by Eric A. Grovender.<br>Ph.D.
APA, Harvard, Vancouver, ISO, and other styles
8

Beaudreuil, Karsenti Séverine. "Cask, une nouvelle molécule impliquée dans la récidive de la hyalinose segmentaire et focale après transplantation rénale." Thesis, Paris 11, 2014. http://www.theses.fr/2014PA11T058.

Full text
Abstract:
La hyalinose segmentaire et focale (HSF) est une maladie rénale sévère dont la physiopathologie est complexe. La récidive de la maladie après transplantation rénale et l’obtention de sa rémission après un traitement par immunoadsorption (IA) illustre l’implication d’un facteur circulant dans sa physiopathologie, capable de se fixer à la protéine A. Récemment, suPAR a été rapporté comme agent causal et marqueur de la HSF. Le premier objectif de notre travail a été de vérifier si suPAR se fixe à la protéine A. Le deuxième objectif a été d’identifier le facteur circulant responsable de la récidive de la HSF après transplantation rénale, à partir de l’analyse par spectrométrie de masse des protéines liées à la colonne de protéine A après (IA). Premièrement, nous avons mesuré la concentration de suPAR par un test ELISA parmi les protéines fixées à la colonne de protéine A après IA chez 7 patients atteints de HSF récidivantes et dans le sérum de 13 patients atteints de HSF récidivantes et de 11 contrôles sains. Le sérum des patients a été immunoadsorbé in vitro sur bille de protéine A sépharose. Nous avons quantifié suPAR avant et après la procédure et dans l’éluat des protéines fixées à la protéine A. La concentration de suPAR est plus élevée chez les patients atteints de HSF récidivantes par rapport aux groupes contrôles. La concentration de suPAR est très faible dans les proteines éluées à partir de la colonne de protéine A, indiquant que suPAR ne se lie pas à la protéine A et n’est pas le facteur circulant élué par les colonnes de protéines A. Deuxièmement, nous avons identifié le FC à partir des protéines fixées à la colonne de protéine A par une caractérisation des protéines par spectrométrie de masse chez des patients traités pour récidive de HSF et chez un patient contrôle. Nous avons recherché le FC dans le sérum de patient atteint de HSF, de patient ayant une néphropathie diabétique et chez des contrôles sains. L’effet de la protéine recombinante du FC a été testé in vitro sur une culture de podocytes et in vivo chez la souris. Nous avons identifié une forme sérique de CASK (calcium calmoduline sérine thréonine kinase), à partir des protéines fixées à la colonne de protéine A après IA. CASK est présente uniquement dans le sérum de patients atteints de HSF et non dans les groupes contrôles. In vitro, la protéine recombinante de CASK (CASKr) induit une redistribution de l’actine du cytosquelette des podocytes en culture par une interaction avec CD98. CASKr altére la perméabilité des podocytes à l’abumine et induit in vivo une protéinurie chez la souris associé à un effacement des pédicelles.En conclusion, suPAR ne se fixe pas à la protéine A ni in vivo ni in vitro. Une forme sérique de CASK est impliqué dans la récidive de la HSF avec comme cible potentiel CD98 sur le podocyte<br>Focal and segmental glomerulosclerosis (FSGS) is a serious disease, the pathogenesis of which is unknown. Its recurrence after transplantation (Tx) and its partial remission after treatment with immunoadsorption (IA) on a protein A column indicate the existence of a circulating factor (CF) responsible for the disease that is able to bind to a protein A column. Recently, the soluble receptor of urokinase (suPAR) was described as the factor responsible for FSGS. The first aim of my work was to test the capacity of suPAR to bind to protein A and to be eliminated by IA. The second aim was to identify the CF responsible of the recurrence of the disease after renal transplantation from the analysis of proteins eluted from protein-A columns from patients with rFSGS who had undergone therapeutic (IA). First, we measured suPAR in eluates of protein A columns from 7 patients with recurrent FSGS after Tx (rFSGS) treated with IA, and in the serum of 13 patients with rFSGS and 11 healthy donors (HD). Additionally, the plasma of these patients was immunoadsorbed in vitro on a protein A Sepharose column and we quantified suPAR in the eluates and in pre- and post-column samples. The concentration of suPAR was higher in the plasma of patients with rFSGS than in the plasma of HD patients. However, the concentration of suPAR was similar before and after IA on protein A for the rFSGS and HD samples. The suPAR concentration was very low in the eluates from protein A columns incubated with plasma from HD or rFSGS patients. However, 85% of rFSGS patients showed a decrease in immunoglobulin G and proteinuria. Secondly, we analyzed proteins eluted from protein-A columns from patients with rFSGS who had undergone therapeutic immunoadsorption. Compared to control a differential band was identified by mass spectrometry. The expression of this protein was tested by immunochemical methods in sera from healthy controls, from patients with proteinuria caused by diabetic nephropathy, and from rFSGS patients. The effect of the recombinant protein was evaluated in vitro (podocytes) and in vivo experiments (mice). A soluble form of calcium/calmodulin-dependent serine/threonine kinase (CASK) eluted from protein-A columns was identified by mass spectrometry. CASK was immunoprecipitated only in the sera from patients with rFSGS. Recombinant CASK induced reorganization of the actin cytoskeleton of cultured podocytes through an interaction with CD98 at the cell surface. In vitro, CASK increased the permeability of podocyte monolayers, and induced proteinuria and foot-process effacement in miceIn conclusion, suPAR does not significantly bind to protein A in vitro or in vivo. Soluble CASK acts as a permeability factor in patients with rFSGS bindinding CD98 on podocytes
APA, Harvard, Vancouver, ISO, and other styles
9

Chen, Jianqing. "Radiolabeling and biotinylation of internalizing monoclonal antibody chimeric BR96 potential use for extracorporeal immunoadsorption with enhanced tumor radioactivity retention of iodine, indium and rhenium /." Lund : Lund University, the Jubileum Institute, Dept. of Radiation Physics, 1997. http://catalog.hathitrust.org/api/volumes/oclc/39725797.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Agossou, Martin. "Etude statique et cinétique de l'adsorption sur amberlites et charbons." Tours, 1986. http://www.theses.fr/1986TOUR4012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Immunoadsorption"

1

1962-, Meier T., and Fahrenholz F, eds. A laboratory guide to biotin-labeling in biomolecule analysis. Birkhäuser Verlag, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Krishna, Mallia A., and Smith Paul K, eds. Immobilized affinity ligand techniques. Academic Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mohr, Peter. Immunosorption techniques: Fundamentals and applications. Akademie Verlag, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Affinity and Immunoaffinity Purification Techniques. EATON PUBLISHING, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mallia, A. Krishna. Immobilized Affinity Ligand Techniques. Elsevier Science & Technology Books, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Noutsias, Michel, and Bernhard Maisch. Myocarditis and pericarditis. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0058.

Full text
Abstract:
Transition of acute myocarditis to dilated cardiomyopathy occurs in approximately 20% of patients within a follow-up period of 33 months. Recent research has revealed the adverse prognostic impact of several clinical parameters for this scenario. Acute myocarditis and its sequelae dilated cardiomyopathy and inflammatory cardiomyopathy are often caused by viral infections. Histological evaluation of endomyocardial biopsies is critical for the diagnosis of the cardiomyopathy entity and for the clinical management of around 20% of the patients. Additionally, contemporary diagnostic procedures of endomyocardial biopsies are indispensable for the selection of inflammatory cardiomyopathy patients who will likely benefit from immunosuppression or antiviral (interferon) treatment. Immunoadsorption, with subsequent immunoglobulin substitution, is a further promising immunomodulatory treatment option for dilated cardiomyopathy patients, targeting primarily the anticardiac autoantibodies. Cardiac magnetic resonance has emerged as a valuable diagnostic approach for myocarditis and pericarditis. Myocardial late gadolinium enhancement has been associated with adverse outcome and sudden cardiac death. Bridging of the first 3–6 months with a wearable cardioverter–defibrillator, until a definitive decision on the implantation of an implantable cardioverter–defibrillator, is a growingly recognized cornerstone in the clinical management of patients with acute myocarditis with depressed left ventricular ejection fraction of &lt;40% and new-onset dilated cardiomyopathy, respectively. Acute pericarditis is labelled idiopathic or suspected viral without adequate proof of the respective aetiology. Non-steroidal anti-inflammatory drugs and colchicine are proven and safe therapeutic mainstays for pericarditis, including the first attack. Pericardiocentesis is a lifesaving treatment of cardiac tamponade. Pericardioscopy and epicardial biopsies can contribute to the aetiological differentiation of pericardial effusions.
APA, Harvard, Vancouver, ISO, and other styles
7

Noutsias, Michel, and Bernhard Maisch. Myocarditis and pericarditis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199687039.003.0058_update_001.

Full text
Abstract:
Transition of acute myocarditis to dilated cardiomyopathy occurs in approximately 20% of patients within a follow-up period of 33 months. Recent research has revealed the adverse prognostic impact of several clinical parameters for this scenario. Acute myocarditis and its sequelae dilated cardiomyopathy and inflammatory cardiomyopathy are often caused by viral infections. Histological evaluation of endomyocardial biopsies is critical for the diagnosis of the cardiomyopathy entity and for the clinical management of around 20% of the patients. Additionally, contemporary diagnostic procedures of endomyocardial biopsies are indispensable for the selection of inflammatory cardiomyopathy patients who will likely benefit from immunosuppression or antiviral (interferon) treatment. Immunoadsorption, with subsequent immunoglobulin substitution, is a further promising immunomodulatory treatment option for dilated cardiomyopathy patients, targeting primarily the anticardiac autoantibodies. Cardiac magnetic resonance has emerged as a valuable diagnostic approach for myocarditis and pericarditis. Myocardial late gadolinium enhancement has been associated with adverse outcome and sudden cardiac death. Bridging of the first 3 months with a wearable cardioverter–defibrillator, until a definitive decision on the implantation of an implantable cardioverter–defibrillator, is a growingly recognized cornerstone in the clinical management of patients with acute myocarditis with depressed left ventricular ejection fraction of &lt;40% and new-onset dilated cardiomyopathy, respectively. Acute pericarditis is labelled idiopathic or suspected viral without adequate proof of the respective aetiology. Non-steroidal anti-inflammatory drugs and colchicine are proven and safe therapeutic mainstays for pericarditis, including the first attack. Pericardiocentesis is a lifesaving treatment of cardiac tamponade. Pericardioscopy and epicardial biopsies can contribute to the aetiological differentiation of pericardial effusions.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Immunoadsorption"

1

Staudt, Alexander, and Stephan B. Felix. "Immunoadsorption in Dilated Cardiomyopathy." In Progress and Challenges in Transfusion Medicine, Hemostasis, and Hemotherapy. KARGER, 2008. http://dx.doi.org/10.1159/000176772.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Felix, Stephan B., and Alexander Staudt. "Immunoadsorption in dilated cardiomyopathy patients." In Inflammatory Cardiomyopathy (DCMi). Birkhäuser Basel, 2010. http://dx.doi.org/10.1007/978-3-7643-8352-7_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chamling, Bishwas, Stephanie Könemann, Marcus Dörr, and Stephan B. Felix. "Immunomodulation and Immunoadsorption in Inflammatory Dilated Cardiomyopathy." In Myocarditis. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-35276-9_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fer, Mehmet F., and Robert K. Oldham. "Protein A Immunoadsorption/Immunoactivation: A Critical Review." In Immune Complexes and Human Cancer. Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-4931-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Marschall, Paul, Timm Laslo, Wolfgang Hoffmann, Kerstin Weitmann, and Steffen Flessa. "Assessing Individualized Medicine—The Example of Immunoadsorption." In Individualized Medicine. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-11719-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Handisurya, Ammon, Christof Aigner, Benjamin Schairer, and Kurt Derfler. "Therapeutic Plasma Exchange and Immunoadsorption: Indications and Implementation." In Advances and Controversies in Hematopoietic Transplantation and Cell Therapy. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-55131-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Orlowski, Alejandro, and Thomas Weber. "Selective Anti-AAV Antibody Depletion by Hemapheresis and Immunoadsorption." In Methods in Molecular Biology. Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2707-5_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Leventhal, J. R. "Removal of Natural Antibodies by Immunoadsorption: Results of Experimental Studies." In Xenotransplantation. Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60572-7_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hellström, Karl Erik, Ingegerd Hellström, Harry W. Snyder, Joe P. Balint, and Frank R. Jones. "Blocking (Suppressor) Factors, Immune Complexes, and Extracorporeal Immunoadsorption in Tumor Immunity." In Immune Complexes and Human Cancer. Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-4931-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bevan, D. J., B. S. Carey, R. W. Vaughan, et al. "Anticipation of highly sensitised renal patients’ immunoadsorption requirements by prescreening using protein A minicolumns." In Transplant International. Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-662-00818-8_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immunoadsorption"

1

Esteves, M., M. Nagler, C. Bocksrucker, B. Mansouri, and M. Daskalakis. "Immunoadsorption for the Treatment of Acquired Haemophilia: A Systematic Review." In 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Haschkovitz, H., O. Warchol, A. Dunky, G. Leitner, N. Worel, and P. Höcker. "FRI0029 Treatment of therapy-resistant rheumatoid arthritis (ra) with immunoadsorption." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.1158.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zeng, P., and H. Zeng. "AB0966 The clinical observation of immunoadsorption in treatment of children with refractory autoimmune diseases." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Egenlauf, Benjamin, Christian Nagel, Ralf Ewert, et al. "Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa3533.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kong, X., Y. Xing, C. Liu, and M. Zhao. "AB0476 The efficacy of immunoadsorption with infliximab theraepy on the modulation of disease activity in patients with severe rheumatoid arthritis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3602.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Robertson, A., R. Issitt, R. Crook, et al. "D2.3 An ex-vivo model for the incorporation of immunoadsorption into the extracorporeal circuit: a novel method for abo incompatible heart transplantation." In Great Ormond Street Hospital Conference. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-084620.35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wilhelm, O., R. Hafter, and H. Graeff. "FIBRONECTIN-FIBRIN-COMPLEXES : AN IMMUNOASSAY TO EVALUATE THEIR FUNCTION IN COAGULATION DISORDERS AND TUMOR SITUATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643194.

Full text
Abstract:
Fibronectin and fibronectin degradation products interact with fibrin(ogen) by non-covalent and by factor XIII catalyzed covalent binding. In certain physiological or pathophysiological situations these complexes may be of considerable importance. It was the aim of this study to accumulate more information of the function of this proteininteraction. Immunoadsorption in combination with Westernblotting with different monoclonal and polyclonal antibodies demonstrate several fibronectin-fibrin(ogen)-complexes in tumor ascites. For further information we established an immunoassay to measure these complexes. As the capture antibody we used a polyclonal fibronectin antibody and as the tag antibody a monoclonal fibrin(ogen) antibody. In this immunoassay we observed a decrease of these complexes from very high values during the therapy of disseminated intra-vascular coagulation besides also a decrease of high molecular weight fibrin derivatives and fibronectin split products. We also found elevated levels in ascitic fluid and plasma of patients with advanced ovarian cancer (x=202,3± SD 45.1 ng/ml fibrinogen equivalent) in comparison to a control group with benign gynecological diseases (X= 102,9± SD 14,9 ng/ml fibrinogen equivalent). In conclusion we suggest that during intravascular coagulation fibronectin binds fibrin derivatives for elimination from plasma. In the tumor situation these complexes may stem from the fibronectin-fibrin-gel-matrix surrounding the tumor by proteolytical degradation and subsequent release into the ascites, (supported by Deutsche Forschungsgemeinschaft, SFB207, A2).
APA, Harvard, Vancouver, ISO, and other styles
8

Gheysen, D., L. Piérard, P. Jacobs, H. R. Lijnen, A. Bollen, and D. Collen. "PROPERTIES OF A HUMAN RECOMBINANT FUSION PROTEIN OF THE ‘FINGER’ DOMAIN OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) AND A TRUNCATED SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (scu-PA)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643941.

Full text
Abstract:
A hybrid between human tissue-type plasminogen activator (t-PA) and human single chain urokinase-type plasminogen activator (scu-PA) was obtained by ligation of cDNA fragments encoding the NH2-terminal amino acids 1 to 67 of t-PA and the COOH-ter-minal amino acids 136 to 411, of scu-PA. Both this chimaeric cDNA and cDNA encoding scu-PA were expressed in a mammalian system (HAK-cells) using bovine papilloma virus (BPV) derived vectors. Two stable cell lines were obtained which secreted the recombinant hybrid and the scu-PA at 1 μg/ml and 2 μg/ml u-PA related antigen respectively into the culture medium. Following purification by Zinc chelate Sepharose, immunoadsorption chromatography, benzamidine-Sepharose and Ultrogel AcA44 gel filtration, highly purified proteins were obtained with a yield of about 200 μg/1. SDS gel electrophoresis under reducing conditions showed single bands with M 43,000 and M 50,000 respectively. Following conversion to urokinase with plasmin, both proteins had a specific amidolytic activity comparable to that of natural scu-PA. Both proteins activated plasminogen directly with km1.4 and 0.5 μM and k2 0.0034 s and 0.0027 s . Neither protein bound specifically to fibrin.Thus the fusion of the finger-like domain of t-PA to the COOH-terminal part of scu-PA does not confer fibrin affinity of t-PA to this chimaeric protein. However, peptide material can be fused to the COOH-terminal part of scu-PA without perturbing its enzymatic properties.
APA, Harvard, Vancouver, ISO, and other styles
9

Carvalho, Isabella Delfim de, Felipe Iankelevich Baracat, and Lucas Farina Lima. "Immunoglobulin versus Plasmapheresis in treatment of Myasthenia Gravis: a systematic review." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.366.

Full text
Abstract:
Introduction: Myasthenia Gravis (MG) is an autoimmune and neuromuscular disease. The treatment of immunomodulation consists of intravenous immunoglobulin (IVIg), immunoadsorption (IA), plasmapheresis (PLEX) or double filtration plasmapheresis (DFPP). This systematic review aims to compare therapy modalities in MG crisis. Methods: The studies were identified through research in electronic databases and analyzed individually to clarify their methodological quality (through the Jadad and Newcastle Ottawa scale). Clinical trials randomized or not, and retrospective studies were included. The review included 1,983 patients in nine studies, the result analysis groups were divided into: IVIg x PLEX in the crises; IVIg x PLEX in the pre-thymectomy treatment phase and IVIg x DFPP in the myasthenic crisis. The evaluated outcomes were clinical improvement, adverse effects and length of hospital stay. Results: Immunomodulatory therapy when applied prior to thymectomy was shown to be effective in reducing symptoms and post-thymectomy hospitalization, with IVIg slightly higher, while PLEX showed more side effects. Therapy during crises in both interventions proved to be effective after the 14th start of treatment, in addition to IVIg being slightly superior. Treatment with IVIg was also economically favorable, due to the lower need for hospitalizations. IVIg proved to be inferior to therapy with DFPP and IA, mainly in reducing the need for hospitalization. Conclusion: It is concluded that IVIg therapy is a good therapeutic option in cases of crisis and when available, therapies with DFPP and IA should be the choices, aiming at less complications.
APA, Harvard, Vancouver, ISO, and other styles
10

Wilhelm, O., A. Henschen, R. Hafter, and H. Graeff. "TUMOR-ASSOCIATED FIBRINOLYSIS IN OVARIAN CARCINOMA - HPLC AND N-TERMINAL AMINO ACID ANALYSIS REVEAL THE PATHWAY OF DEGRADATION OF CROSSLINKED FIBRIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643189.

Full text
Abstract:
Crosslinked fibrin has been demonstrated by immunohistochemi-cal tests to occur around tumor plugs, on the surface and in the stroma of the tumor in ovarian cancer. High levels of D-Dimer (200-800μg/ml), the characteristic terminal degradation product of crosslinked fibrin, are found in ascitic fluid of patients with advanced ovarian cancer. These findings suggest that fibrin polymerisation and degradation are related to and even may influence tumor growth. The kind of proteases which are responsible for degradation of crosslinked fibrin is, however, unknown.lt was the aim of this study to evaluate whether plasmin and/or other proteases are involved in tumor-associated fibrinolysis. Therefore the total high-molecular-weight fibrin degradation products in ascitic fluid were purified by protamine sulfate precipitation, gel filtration, immunoadsorption and compared with the components of plasmin-degraded crosslinked fibrin, i.e. DD,DY,YX,DXD and DXY, by direct SDS-PAGE in the absence of mercaptoethanol and after excision of the bands, mercaptolysis and re-electrophoresis. Pronounced similarity between the two sets of fragments was observed. For further information the fragments from the two sources were mercaptolysed and their polypeptide chain components separated by reversed-phase high-performance liquid chromatography, the components being identified by N-terminal sequence analysis and SDS-PAGE. Highly similar patterns were obtained and components corresponding to γ-γ ,γ-γ1, β, β2 and α1 could be recognized. The findings provide strong evidence for plasmin being the primary protease involved in ovarian carcinoma-related fibrinolysis, (supported by Deutsche Forschungsgemeinschaft.SFB 207, A2).
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immunoadsorption' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography